Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00760708 · ClinicalTrials.gov registry record

Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

A clinical trial, sponsored by UConn Health.

Terminated
Registry status
221
Enrollment target

NCT00760708 is a clinical trial that was terminated before completion, run by UConn Health. The registered enrollment target is 221 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00760708 was terminated before completion, sponsored by UConn Health.

TERMINATED
Registry status
221 participants
Enrollment target

Study Summary

Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosine is a naturally occurring substance in the body that can increase blood flow. Adenosine is normally removed from the bloodstream by an adenosine transporter, which is a protein that takes up adenosine from the blood into cells. The increase in adenosine levels in the blood is variable, and the cause for this variability is unknown. A mutation for this transporter gene may contribute to this variability, and may alter its function. Thus, the purpose of this study is to determine the relationship between the mutation and the transporter function.

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2005-09
Est. Completion 2011-12

Sponsor

UConn Health

178 total trials

What the Registry Record Tells You About NCT00760708

The ClinicalTrials.gov registry entry for NCT00760708 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00760708 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00760708 about?

NCT00760708 is a clinical study titled "Circulating Adenosine Levels Before and After Intravenous (IV) Persantine". Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosine is a naturally occurring substance in the body that can increase blood flow. Adenosine is normally...

What is the current status of trial NCT00760708?

This trial is currently terminated. The enrollment target is 221 participants. The study started on 2005-09. Estimated completion is 2011-12.

Who is sponsoring clinical trial NCT00760708?

This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.